KIT and acute myeloid leukemia: According to a phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin, especially for c-kit positive recurrent acute myeloid leukemia, cytotoxic therapy that includes imatinib mesylate for relapsed AML was effective [32].